Takeda Divests Assets to Hypera for $825M

Takeda Pharmaceutical Co. Ltd. has entered an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera S.A., Brazil's largest pharmaceutical company, for $825 million.

The portfolio includes OTC and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda's Growth & Emerging Markets Business Unit.

Takeda anticipates that approximately 300 commercial employees supporting the divested assets will be given the opportunity to transition over to Hypera Pharma at the close of this transaction, which is expected in 2H20, subject to customary closing conditions.

This divestment enables Takeda to focus its investments in emerging markets and Latin America that center on its innovative medicines across Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience.

This is Takeda's fifth divestment over the last 12 months, contributing to the company's goal to divest approximately $10 billion in non-core assets.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.